ArticleBMJ (Clinical research ed.)2020
Financial ties between leaders of influential US professional medical associations and industry: cross sectional study.
Article in BMJ (Clinical research ed.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review.British journal of cancer · 2022Pooled it
- Navigating the Prescription Drug Information System.Clinical pharmacology and therapeutics · 2026Review
- Doctors' Conflict-of-Interest; What it Looks Like and What to do About it.International journal of social determinants of health and health services · 2026Article
- Food industry's interactions with nutrition professionals in Australia: a survey.Public health nutrition · 2026Article
- Industry-Reported Financial Relationships Among American Ophthalmology Society Board Members.Clinical & experimental ophthalmology · 2026Article
- Evaluating conflict-of-interest governance among Canadian medical societies using a novel assessment tool: A cross-sectional study.PloS one · 2026Article
- Advancing equitable access to innovation in breast cancer.NPJ breast cancer · 2025Article
- The Rise of Clinical Decision Support Algorithms in Pain Management 2009-2024.Journal of general internal medicine · 2025Article
- Care of Diabetes and the Sacrifice of Evidence-Based Medicine and Health Equity.Journal of general internal medicine · 2024Article
- Source credibility: a necessary North Star in cancer care.BJC reports · 2024Article
- Factors affecting decisions of an HMO Drug Exemptions Committee on individual patient requests for coverage of non-formulary drugs.Israel journal of health policy research · 2024Article
- Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan.BMC medical ethics · 2024Article
- Industry Payments to United States Rheumatologist-Authors of Publications in High-Impact Rheumatology Journals.ACR open rheumatology · 2023Article
- Article
- What did the scientific literature learn from internal company documents in the pharmaceutical industry? A scoping review.Cochrane evidence synthesis and methods · 2023Review
- Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019.BMJ open · 2023Article
- SAGES perspective: professional medical associations, commercial interests, and conflicts of interest.Surgical endoscopy · 2023Article
- Rebalancing commercial and public interests in prioritizing biomedical, social and environmental aspects of health through defining and managing conflicts of interest.Frontiers in medicine · 2023Review
- Incentivisation practices and their influence on physicians' prescriptions: A qualitative analysis of practice and policy in Pakistan.PLOS global public health · 2023Article
- Trends in Industry Payments to Physicians in the First 6 Years After Graduate Medical Training.JAMA network open · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the nature and extent of financial relationships between leaders of influential professional medical associations in the United States and pharmaceutical and device companies.
designCross sectional study.
settingProfessional associations for the 10 costliest disease areas in the US according to the US Agency for Healthcare Research and Quality. Financial data for association leadership, 2017-19, were obtained from the Open Payments database. POPULATION: 328 leaders, such as board members, of 10 professional medical associations: American College of Cardiology, Orthopaedic Trauma Association, American Psychiatric Association, Endocrine Society, American College of Rheumatology, American Society of Clinical Oncology, American Thoracic Society, North American Spine Society, Infectious Diseases Society of America, and American College of Physicians.
main outcome measuresProportion of leaders with financial ties to industry in the year of leadership, the four years before and the year after board membership, and the nature and extent of these financial relationships.
results235 of 328 leaders (72%) had financial ties to industry. Among 293 leaders who were medical doctors or doctors of osteopathy, 235 (80%) had ties. Total payments for 2017-19 leadership were almost $130m (£103m; €119m), with a median amount for each leader of $31 805 (interquartile range $1157 to $254 272). General payments, including those for consultancy and hospitality, were $24.8m and research payments were $104.6m-predominantly payments to academic institutions with association leaders named as principle investigators. Variation was great among the associations: median amounts varied from $212 for the American Psychiatric Association leaders to $518 000 for the American Society of Clinical Oncology.
conclusionsFinancial relationships between the leaders of influential US professional medical associations and industry are extensive, although with variation among the associations. The quantum of payments raises questions about independence and integrity, adding weight to calls for policy reform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.